April 19, 2021

Randomized Comparative Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• [Pre-print, not peer-reviewed] Patients with moderate COVID-19 (n=40) randomized to treatment with the novel anti-inflammatory medication PNB001 had lower clinical severity scores assessed by the 8-point WHO Ordinal Scale for COVID-19 at day 14 than patients who received standard of care alone (score 0.2 vs. 1.1, p<0.05). The multicenter randomized trial did not detect a difference in the other primary endpoint of mortality, with 1 death in the PNB001 group and 2 deaths in the standard of care group. Three severe adverse events occurred, though none were found to be related to the study medication. 

Lattman et al. (Apr 16, 2021). Randomized Comparative Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients. Pre-print downloaded Apr 19 from https://doi.org/10.1101/2021.04.16.21255256